少或许就足够了：低风险复发霍奇金淋巴瘤的无移植未来。 - Suppr

Suppr

超能文献

Less may be enough: a transplant-free future for low-risk relapsed Hodgkin lymphoma.

作者信息

Forlenza Christopher J, Castellino Sharon M

机构信息

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Department of Pediatrics, Emory University Hospital/Winship Cancer Institute, Atlanta, GA, USA.

出版信息

Transl Pediatr. 2025 Aug 31;14(8):1741-1745. doi: 10.21037/tp-2025-346. Epub 2025 Aug 27.

DOI:10.21037/tp-2025-346

PMID:40949913

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12433037/

Abstract

摘要

相似文献

Less may be enough: a transplant-free future for low-risk relapsed Hodgkin lymphoma.少或许就足够了：低风险复发霍奇金淋巴瘤的无移植未来。

Transl Pediatr. 2025 Aug 31;14(8):1741-1745. doi: 10.21037/tp-2025-346. Epub 2025 Aug 27.

Autologous Stem Cell Transplant in Fit Patients With Late Relapsed Diffuse Large B-Cell Lymphoma That Responded to Salvage Chemotherapy.适合接受自体干细胞移植的晚期复发弥漫性大B细胞淋巴瘤患者，这些患者对挽救性化疗有反应。

Transplant Cell Ther. 2024 Oct;30(10):1001.e1-1001.e12. doi: 10.1016/j.jtct.2024.07.008. Epub 2024 Jul 10.

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data.自体移植后复发/难治性霍奇金淋巴瘤中维布妥昔单抗治疗：荟萃分析与历史数据对比

Curr Med Res Opin. 2015 May;31(5):993-1001. doi: 10.1185/03007995.2015.1030378. Epub 2015 Apr 9.

Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma.24 个月无进展生存作为自体干细胞移植后复发或难治性弥漫性大 B 细胞淋巴瘤的里程碑。

Transplant Cell Ther. 2022 Sep;28(9):610-617. doi: 10.1016/j.jtct.2022.06.015. Epub 2022 Jun 22.

High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.成人滤泡性淋巴瘤采用自体干细胞移植高剂量疗法与化疗或免疫化疗的比较

Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD007678. doi: 10.1002/14651858.CD007678.pub2.

Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.对于复发和难治性霍奇金淋巴瘤，可以通过大剂量化疗和自体干细胞移植来克服化疗耐药性。

Ann Oncol. 2014 Nov;25(11):2218-2223. doi: 10.1093/annonc/mdu387. Epub 2014 Aug 22.

High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma.复发/难治性霍奇金淋巴瘤患者接受大剂量化疗后进行自体干细胞移植。

Cochrane Database Syst Rev. 2013 Jun 20;2013(6):CD009411. doi: 10.1002/14651858.CD009411.pub2.

Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and Analysis.自体干细胞移植在 70 多岁老年淋巴瘤患者中的应用：结果与分析。

Oncologist. 2018 May;23(5):624-630. doi: 10.1634/theoncologist.2017-0499. Epub 2017 Dec 28.

Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer).纳武单抗用于成人霍奇金淋巴瘤（使用RobotReviewer软件进行的快速综述）

Cochrane Database Syst Rev. 2018 Jul 12;7(7):CD012556. doi: 10.1002/14651858.CD012556.pub2.

Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.嵌合抗原受体 (CAR) T 细胞疗法治疗复发或难治性弥漫性大 B 细胞淋巴瘤患者。

Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2.

本文引用的文献

Transplant-Free Approach in Relapsed Hodgkin Lymphoma in Children, Adolescents, and Young Adults: A Nonrandomized Clinical Trial.儿童、青少年和青年复发性霍奇金淋巴瘤的无移植治疗方法：一项非随机临床试验

JAMA Oncol. 2025 Mar 1;11(3):249-257. doi: 10.1001/jamaoncol.2024.5627.

Transplant-Free Salvage Therapy for Low-Risk Relapsed Pediatric Hodgkin Lymphoma: A Nonrandomized Clinical Trial.低危复发性儿童霍奇金淋巴瘤的非移植挽救性治疗：一项非随机临床试验

JAMA Oncol. 2025 Mar 1;11(3):340-342. doi: 10.1001/jamaoncol.2024.5648.

Transplant and Nontransplant Salvage Therapy in Pediatric Relapsed or Refractory Hodgkin Lymphoma: The EuroNet-PHL-R1 Phase 3 Nonrandomized Clinical Trial.儿童复发或难治性霍奇金淋巴瘤的移植和非移植挽救治疗：欧洲儿童霍奇金淋巴瘤网络-1（EuroNet-PHL-R1）3期非随机临床试验

JAMA Oncol. 2025 Mar 1;11(3):258-267. doi: 10.1001/jamaoncol.2024.5636.

Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.纳武利尤单抗+AVD 方案治疗晚期经典型霍奇金淋巴瘤。

N Engl J Med. 2024 Oct 17;391(15):1379-1389. doi: 10.1056/NEJMoa2405888.

Late morbidity and mortality after autologous blood or marrow transplantation for lymphoma in children, adolescents and young adults-a BMTSS report.儿童、青少年和青年淋巴瘤自体血或骨髓移植后的迟发性发病率和死亡率 - BMTSS 报告。

Leukemia. 2024 Mar;38(3):601-609. doi: 10.1038/s41375-024-02144-7. Epub 2024 Feb 19.

Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma.基于检查点抑制剂的挽救方案在自体干细胞移植前可改善复发/难治性经典霍奇金淋巴瘤的无事件生存。

Am J Hematol. 2023 Mar;98(3):464-471. doi: 10.1002/ajh.26827. Epub 2023 Jan 11.

Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults.纳武单抗和本妥昔单抗联合或不联合苯达莫司汀治疗儿童、青少年和年轻成人复发/难治性霍奇金淋巴瘤。

Blood. 2023 Apr 27;141(17):2075-2084. doi: 10.1182/blood.2022017118.

Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma.贝林妥欧单抗联合化疗治疗儿科高危霍奇金淋巴瘤。

N Engl J Med. 2022 Nov 3;387(18):1649-1660. doi: 10.1056/NEJMoa2206660.

Total late effect burden in long-term lymphoma survivors after high-dose therapy with autologous stem-cell transplant and its effect on health-related quality of life.大剂量化疗自体造血干细胞移植后长期淋巴瘤幸存者的晚期总效应负担及其对健康相关生活质量的影响。

Haematologica. 2022 Nov 1;107(11):2698-2707. doi: 10.3324/haematol.2021.280413.

Vital organ sparing with proton therapy for pediatric Hodgkin lymphoma: Toxicity and outcomes in 50 patients.质子治疗儿童霍奇金淋巴瘤的保留重要器官效果：50 例患者的毒性和结局。

Radiother Oncol. 2022 Mar;168:46-52. doi: 10.1016/j.radonc.2022.01.016. Epub 2022 Jan 29.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验